Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,017 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Infection Clear all
Completed No phase listed Observational Accepts healthy volunteers

Immune-cell Membrane Trafficking

NCT00638521
View directory record Official record
Conditions
Severe Trauma
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Nov 5, 2026, 1:30 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates

NCT06824350
View directory record Official record
Conditions
Sepsis, Neonatal Mortality, Antibiotic Resistant Infection, Enteric Infections, Serious Bacterial Infection
Interventions
chlorination for water disinfection and surface disinfection, infection prevention and control messaging
Device · Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
Not listed
Enrollment
45,450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 5, 2026, 1:30 AM EST
Not listed Phase 2 Interventional Accepts healthy volunteers

Machine Learning Sepsis Alert Notification Using Clinical Data

NCT04005001
View directory record Official record
Conditions
Sepsis, Severe Sepsis, Septic Shock
Interventions
HindSight, InSight
Other
Lead sponsor
Dascena
Industry
Eligibility
18 Years and older
Enrollment
37,986 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Springfield, Massachusetts • Camden, New Jersey • Cape May, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Nov 5, 2026, 1:30 AM EST
Completed Not applicable Interventional

Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2

NCT02829060
View directory record Official record
Conditions
Nephrolithiasis, Urinary Tract Infection (UTI), Sepsis
Interventions
Nitrofurantoin 100 MG, 7d, Gentamicin, 5mg/kg, Ampicillin 2g, Nitrofurantoin 100 mg, 48 hrs, Gentamicin, 80 mg, 7d, Gentamicin, 80 mg, 48hr
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Nov 5, 2026, 1:30 AM EST
Completed No phase listed Observational

REMISE Study: REMnant Biospecimen Investigation in SEpsis

NCT05684133
View directory record Official record
Conditions
Sepsis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Nov 5, 2026, 1:30 AM EST
Completed No phase listed Observational

Systems Biology Approach to Cognitive Impairment After SepsiS

NCT03015584
View directory record Official record
Conditions
Sepsis, Cognitive Impairment
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Nov 5, 2026, 1:30 AM EST
Completed Not applicable Interventional

A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common

NCT00002325
View directory record Official record
Conditions
Mycoses, HIV Infections, Coccidioidomycosis
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Phoenix, Arizona • Tucson, Arizona • Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 5, 2026, 1:30 AM EST
Completed No phase listed Observational Results available

Inflammatory Cytokine Quantification in Infants

NCT01155830
View directory record Official record
Conditions
Sepsis, Congenital Diaphragmatic Hernia, Neonatal Cardiopulmonary Failure
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 2 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Nov 5, 2026, 1:30 AM EST
Completed Phase 3 Interventional

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

NCT00001810
View directory record Official record
Conditions
Aspergillosis, Candidiasis, Fungemia, Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 5, 2026, 1:30 AM EST
Completed No phase listed Observational

Regression Discontinuity Design to Evaluate of Drotrecogin Alpha Effectiveness

NCT02843685
View directory record Official record
Conditions
Sepsis
Interventions
Drotrecogin alfa activated
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
Not listed
Enrollment
12,492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Nov 5, 2026, 1:30 AM EST
Recruiting No phase listed Observational

PIVO Use for Blood Cultures in the Emergency Department

NCT07348289
View directory record Official record
Conditions
Sepsis, Device Performance, Emergency Medicine
Interventions
PIVO device, a needle-free blood draw device
Device
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Park City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Nov 5, 2026, 1:30 AM EST
Completed Not applicable Interventional Results available

Passive Disinfection Cap Compliance Study

NCT03391960
View directory record Official record
Conditions
Infection, Hospital
Interventions
Passive disinfection device
Device
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Maplewood, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Nov 5, 2026, 1:30 AM EST
Withdrawn Phase 1 Interventional

Pharmacokinetics and Safety of Ticarcillin-clavulanate in Infants

NCT01229046
View directory record Official record
Conditions
Sepsis
Interventions
Ticarcillin-clavulanic acid
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
Up to 90 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Nov 5, 2026, 1:30 AM EST
Completed Phase 1 Interventional

Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia

NCT00001790
View directory record Official record
Conditions
Fever, Mycoses, Neutropenia
Interventions
FK463
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 5, 2026, 1:30 AM EST
Not listed No phase listed Observational

A Biologic Validation of Biomarkers of Progressive NEC & Sepsis

NCT00588718
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
Not listed
Lead sponsor
R. Lawrence Moss
Other
Eligibility
72 Hours to 28 Weeks
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Nov 5, 2026, 1:30 AM EST
Completed No phase listed Observational

Outcomes of Septic Shock Patients Treated With a Metabolic Resuscitation Bundle Consisting of Intravenous Hydrocortisone, Ascorbic Acid and Thiamine.

NCT03913468
View directory record Official record
Conditions
Septic Shock, Ascorbic Acid Deficiency
Interventions
Intravenous Ascorbic Acid
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Nov 5, 2026, 1:30 AM EST
Completed Not applicable Interventional Results available

Impact of a Procalcitonin Testing and Treatment Algorithm on Antibiotic Use and Outcomes in the Pediatric Intensive Care Unit

NCT03440918
View directory record Official record
Conditions
Sepsis, Procalcitonin, Antimicrobial Stewardship
Interventions
Procalcitonin-Guided Antimicrobial Stewardship, Baseline Antimicrobial Stewardship
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
2 Hours to 17 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Nov 5, 2026, 1:30 AM EST
Withdrawn Not applicable Interventional

Sepsis Pre-Alert Monitoring Intervention: Study to Investigate Targeted Enhanced Monitoring for Sepsis

NCT03473769
View directory record Official record
Conditions
Sepsis
Interventions
Vital Signs at 2 Hours, Confusion Assessment method for the ICU (CAM-ICU)
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 110 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Nov 5, 2026, 1:30 AM EST
Completed Phase 1 Interventional

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

NCT01231919
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Aggressive NK-cell Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myeloid/NK-cell Acute Leukemia, Noncutaneous Extranodal Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Nov 5, 2026, 1:30 AM EST
Completed Phase 2 Interventional Results available

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

NCT00392990
View directory record Official record
Conditions
Lymphoma
Interventions
Regimen A, Regimen B
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
8
States / cities
Chicago, Illinois • Maywood, Illinois • Park Ridge, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Nov 5, 2026, 1:30 AM EST
Completed Phase 3 Interventional

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis

NCT04102371
View directory record Official record
Conditions
Shock, Septic
Interventions
Lactated Ringer, Normal Saline, Plasma-lyte
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Months to 17 Years
Enrollment
9,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 5, 2026, 1:30 AM EST
Completed Phase 1 Interventional

Voriconazole to Prevent Systemic Fungal Infections in Children

NCT00005912
View directory record Official record
Conditions
Aspergillosis, Candidiasis, Fungal Diseases, Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 5, 2026, 1:30 AM EST
Terminated Phase 2 Interventional Results available

Esmolol to Treat the Hemodynamic Effects of Septic Shock

NCT02369900
View directory record Official record
Conditions
Septic Shock, Hypotension, Tachycardia
Interventions
Esmolol, Saline
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Nov 5, 2026, 1:30 AM EST
Completed Phase 1 Interventional

Pyroxamide in Treating Patients With Advanced Cancer

NCT00042900
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pyroxamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Nov 5, 2026, 1:30 AM EST